Eli Lilly & Co. announced August 17 it would halt development of its Phase III Alzheimer's drug candidate semagacestat, casting some doubt on the efficacy of novel gamma secretase inhibitor drugs and slowing Lilly's late-stage pipeline as the company struggles to replace future revenues that will be lost to drugs going off patent.
In an interim analysis of two late-stage trials, patients taking orally administered semagacestat not only failed to show improvement, but...